替吉奥单药治疗老年晚期乳腺癌的临床疗效与安全性

目的 观察替吉奥单药治疗老年晚期乳腺癌的疗效与安全性。方法 回顾性分析老年晚期乳腺癌患者65例,研究组32例(S组)：替吉奥 40～60 mg(＜1.25 m²，40 mg; 1.25～1．5 m²，50 mg;＞1.5 m²,60 mg)，于早、晚饭后口服，连服14天，21天重复。对照组33例（X组）：卡培他滨每日2000 mg/m²,分2次,连服14天，21天重复，至少2周期后评价疗效。结果 65例患者均可评价疗效, S组、X组有效率（RR）分别为31.3％(10/32)、27.3％(9/33)，疾病控制率（DCR）分别为78.1％（25/32）、69.7％(23/33）,中位疾病进展时间（TTP）分别为7.5、7.0月，中位总生存时间（OS）分别为17.3、15.2月,两组比较差异无统计学意义（P＞0.05）。研究组与对照组常见的不良反应为骨髓抑制、胃肠道反应、口角炎、乏力，多见Ⅰ～Ⅱ度,可耐受，两组差异无统计学意义；对照组手足综合征明显高于研究组，差异有统计学意义（P=0.000）。 结论 替吉奥单药治疗老年乳腺癌疗效肯定，耐受性好于卡培他滨，值得临床进一步研究、推广。

Efficacy and Safety of S-1 as Monotherapy in Elderly Patients with Advanced Breast Cancer

Objective  To evaluate the efficacy and safety of S-1 monotherapy in elderly patients with advanced breast cancer.Methods  Retrospectively analysis sixty-five elderly patients with advanced breast cancer. The study group(S group,n=32):S-1：40-60 mg(＜1.25 m²，40 mg; 1.25-1．5 m²，50 mg;＞1.5 m²,60 mg， twice/day, oral administration，d1-d14, three weeks was a cycle. The control group(X group,n=33): Capecitabine：2 000 mg/（m²·d）, separated to twice, d1-d14, three weeks was a cycle.The efficacy and toxicity were evaluated by WHO standards after 2-cycle treatment．Results  The efficacy and toxicity could be evaluated in the all 65 patients,the RR of S group and X group was 31.3％(10/32)，27.3％(9/33),the DCR was 78.1％（25/32），69.7％(23/33） , the median TTP was 7.5 ，7.0 months， the OS was 17.3，15.2 months . There was no significant difference（P＞0.05）.The most common toxicities of the two groups were hematological，digestive toxic reactions， stomatitis and feeble，mainly 1-2 degree，and could be well tolerated．The Hand-foot syndrome rate of X group exceeded the S group（P=0.000）.Conclusion  The efficacy of S-1 for elderly patients with advanced breast cancer is significant with well- tolerated toxicity better than Capecitabine，and worth to further study and popularize.